Vir Biotechnology has released the topline data from its Phase 2 PENINSULA trial, which evaluated VIR-2482 for the prevention of seasonal influenza A illness. According to the announcement made on July 20, 2023, VIR BIOTECHNOLOGY Inc. reported that the trial did not meet its primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), there was a..
Cumulus Neuroscience, a global digital health company, recently shared their findings at the AAIC 2023 Annual Meeting and Technology and Dementia Preconference.   The interim analysis of their groundbreaking CNS-101 study revealed that individuals with mild Alzheimer's dementia are not only capable but also willing to participate in intensive home-based functional neurophysiology studies. &n..
The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment.   In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability..
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company specializing in therapies for chronic inflammatory diseases, unveiled additional findings from its pivotal trial for atopic dermatitis during the 2023 World Congress of Dermatology. The data highlighted the effectiveness and safety of rademikibart (formerly known as CBP-201) in treating moderate-to-severe atopi..
